Shares of health insurer Humana Inc. (NYSE:HUM) have endured a rollercoaster ride, witnessing significant rises and falls. The company enjoyed a 15.1% uplift following their last earnings report and saw further advances following Medicare star ratings ruling. Major holders like The Manufacturers Life Insurance Company, RBC Capital, UBS Asset Management, and Glenmede Trust Co significantly upped their position in Humana. However, amidst this optimism, Humana emerged as one of the worst performing healthcare stocks, leaving investors with a 44% loss over the past year.
The firm has battled several headwinds in Q3, experiencing a slump in their stock price after Cigna ended merger speculations. Yet, Humana showed resilience by unveiling Michelle OβHara as Chief Human Resources Officer, raising the price target, and demonstrating strong EPS guidance. Despite a negative impact on membership for its top-rated Medicare plans, Humana demonstrated its fiscal strength by announcing a dividend of $0.885. They also made collaborative strides by partnering with Evergreen Nephrology, aimed at improving health outcomes. Despite the uncertain outlook, Humana stands as a highlighted choice amongst Seth Klarman's top stock picks.
Humana HUM News Analytics from Wed, 31 Jul 2024 07:00:00 GMT to Sat, 30 Nov 2024 10:42:17 GMT - Rating 7 - Innovation 5 - Information 8 - Rumor -4
